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Plasma lipocalin‑2/NGAL 
is stable over 12 weeks 
and is not modulated by exercise 
or dieting
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Elisabeth A. Lambert4,5, Nora E. Straznicky5, Markus P. Schlaich5,6, Murray D. Esler5, 
Brendan J. O’Brien3, Fadi J. Charchar3, Gavin W. Lambert4,5 & Francine Z. Marques1,3,5*
Amongst other immune cells, neutrophils play a key role in systemic inflammation leading to 
cardiovascular disease and can release inflammatory factors, including lipocalin‑2 (LCN2). LCN2 drives 
cardiac hypertrophy and plays a role in maladaptive remodelling of the heart and has been associated 
with renal injury. While lifestyle factors such as diet and exercise are known to attenuate low‑grade 
inflammation, their ability to modulate plasma LCN2 levels is unknown. Forty‑eight endurance 
athletes and 52 controls (18–55 years) underwent measurement for various cardiovascular health 
indicators, along with plasma LCN2 concentration. No significant difference in LCN2 concentration 
was seen between the two groups. LCN2 was a very weak predictor or absent from models describing 
blood pressures or predicting athlete status. In another cohort, 57 non‑diabetic overweight or obese 
men and post‑menopausal women who fulfilled Adult Treatment Panel III metabolic syndrome criteria 
were randomly allocated into either a control, modified Dietary Approaches to Stop Hypertension 
(DASH) diet, or DASH and exercise group. Pre‑ and post‑intervention demographic, cardiovascular 
health indicators, and plasma LCN2 expression were measured in each individual. While BMI fell in 
intervention groups, LCN2 levels remained unchanged within and between all groups, as illustrated 
by strong correlations between LCN2 concentrations pre‑ and 12 weeks post‑intervention (r = 0.743, 
P < 0.0001). This suggests that circulating LCN2 expression are stable over a period of at least 12 weeks 
and is not modifiable by diet and exercise.
High body mass index (BMI) and obesity promote a low-grade chronic systemic inflammatory state, triggering a 
systemic acute phase  response1. Pro-inflammatory acute phase response proteins are then produced and released, 
which can feedback into the chronic inflammatory  phenotype2. Low-grade systemic inflammation also produces 
an ideal environment for the development of cardiovascular (CVD) and renal disease. Inflammatory biomarkers 
such as C-reactive protein (CRP) and the more recently implicated GlycA can predict the risk of CVD many 
years in  advance3,4. Inflammatory pathways are critical for the pathological remodelling of the heart, for example, 
through stimulation of proteins involved in degradation and reconstruction of the  interstitium5–7. This maladap-
tive remodelling is involved in multiple types of CVDs, and may lead to cardiac hypertrophy and heart  failure8.
Neutrophils, the most abundant type of white blood cells in the body, are recognized for their role in the 
atherosclerotic process and their relevance for the development of heart  failure9,10. Among a variety of inflam-
matory factors, neutrophils release lipocalin-2 (LCN2, otherwise known as neutrophil gelatinase-associated 
lipocalin or NGAL), a 25 kDa protein that is upregulated during the acute phase response, and primarily con-
tributes to innate immunity through its function as an iron  chelator11,12. It has been used clinically as a marker 
of renal failure and, more recently, as a marker of increased cardiovascular  risk13–15. Other both immune and 
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non-immune cell types such as cardiomyocytes, fibroendothelial cells, renal cells, and macrophages, have also 
been shown to release  LCN216–19. In the context of cardiac remodelling, LCN2 has been shown to preserve the 
enzymatic activity of matrix metalloprotease-9 (MMP9), a protein heavily involved in the breakdown of the 
 interstitium20,21. LCN2 has also been shown to drive cardiac hypertrophy in vitro and vivo, and was associated 
with left ventricular mass and BMI in  humans19. Importantly, LCN2 was a stronger marker of innate immune 
response, in particular neutrophil function, than CRP or  GlycA19.
The ability of a balanced diet and regular exercise to reduce BMI and the risk of CVD is well  documented22–24. 
In particular, specific diets such as the Dietary Approach to Stop Hypertension (DASH) have been able to reduce 
low-grade inflammation observed as serum CRP  levels25–29. However, whether LCN2 expression can be attenu-
ated by exercise or diet interventions is currently unclear. Here we aimed to determine if LCN2 plasma levels are 
modulated by physical fitness and diet, and to investigate whether LCN2 levels are stable over time.
Results
Relative to controls, endurance athletes were taller, had superior cardiorespiratory fitness as indicated by peak 
oxygen uptake ( ̇VO2peak) (controls vs athletes mean ± SD, units: 42.6 ± 7.1 v 58.0 ± 8.8,  ml.kg−1 min−1), lower resting 
heart rate (68 ± 10.5 v 52 ± 7.8, beats min−1), and BMI (25.9 ± 2.8 v 22.6 ± 2.3) (all P < 0.001, Table 1). The difference 
in plasma LCN2 protein levels between controls and endurance athletes was of borderline statistical significance 
(68.3 ± 21.8 v 75.0 ± 14.8, ng/mL, P = 0.073, Fig. 1). Therefore, a sensitivity analysis was performed to determine 
which cardiovascular health indicators could predict whether an individual belonged to the athlete group or 
control group (athlete status) (Table 2). The analysis showed that athlete status could be predicted correctly in 
94.8% of individuals using BMI, sex, age, and V̇O2peak as predictors, with the model having an overall Cox & Snell 
β value of 0.683. LCN2 concentration, however, was not a significant predictor of athlete status in this model.
To understand whether the borderline difference in plasma LCN2 expression could be explained through 
sex-specific differences, we analysed the cohort by splitting the controls and endurance athletes into male 
and female groups. Male athletes were more similar to sex-matched control group counterparts than when 
compared to female athletes compared to sex-matched controls in terms of cardiovascular health indicators 
(Tables 3, 4). Female athletes had a lower BMI (26.6 ± 3.4 v 20.9 ± 2.3), diastolic blood pressure (DBP) (76.6 ± 8.8 v 
67.7 ± 7.4, mmHg), mean arterial pressure (MAP) (91.0 ± 9.3 v 82.7 ± 6.3, mmHg), central systolic blood pressure 
(SBP) (107.6 ± 11.3 v 96.9 ± 7.0, mmHg), central DBP (77.6 ± 8.8 v 67.8 ± 7.3, mmHg), central MAP (87.7 ± 9.3 
v 77.5 ± 6.9, mmHg), resting heart rate (72.0 ± 9.6 v 52.5 ± 9.9, beats  min−1), and higher V̇O2peak (34.7 ± 4.4 v 
54.6 ± 13.1, ml kg−1.min−1), while male athletes only differed from the controls when looking at BMI (25.6 ± 2.5 
v 23.0 ± 2.2), resting heart rate (67.2 ± 10.7 vs 52.3 ± 7.3, beats  min−1), and V̇O2peak (45.8 ± 5.2 vs 59.0 ± 7.2, 
ml kg−1 min−1) (all P < 0.01). Importantly, the difference in plasma LCN2 expression was of borderline statistical 
significance in male controls compared to male athletes (67.1 ± 22.6 v 75.9 ± 15.3, ng/mL, P = 0.053), while there 
were no differences between controls and athletes in females (70.1 ± 20.6 v 71.5 ± 12.7, ng/mL, P = 0.847) (Fig. 2). 
Thus, a sensitivity analysis was again performed on the male data to test whether athlete status could be predicted 
from LCN2 expression, BMI, age, and V̇O2peak (Table 5). Male athlete status was found to be able to be predicted 
in 90.5% of the data using age and V̇O2peak as inputs, with the model showing an overall Cox & Snell β value of 
0.676. LCN2 expression and BMI were not found to be significant predictors of athlete status. Therefore, males 
and females were grouped for all subsequent analyses.
We also performed sensitivity analyses to determine the influence of LCN2 on SBP, DBP, central SBP and cen-
tral DBP (Tables 6, 7). While a generalised model predicting SBP did not show LCN2 concentration as a signifi-
cant factor, models predicting DBP, central SBP, and central DBP found that LCN2 concentration was a significant 
predictor (P < 0.05, Tables 6, 7). All models explained 21.1% to 29.2% of the variability of the predicted variable 
Table 1.  Characteristics of endurance athletes and controls. Data are expressed as mean ± standard deviation 
from two-tailed independent samples t-tests or Mann–Whitney U-tests, with P-values below 0.05 bolded. 
Variances were equal between groups for all variables except for resting HR. BMI, body mass index; SBP, 
systolic blood pressure; DBP, diastolic blood pressure; HR, resting heart rate; V̇O2peak, maximal aerobic 
(cardiorespiratory) fitness.
Variable Controls (n = 48) Endurance athletes (n = 52) P value
Men/women (n) 34/14 41/11 0.36
Age (years) 30.5 ± 11.3 33.4 ± 11.1 0.19
BMI (kg/m2) 25.9 ± 2.8 22.6 ± 2.3 < 0.001
SBP (mmHg) 125.6 ± 10.0 122.6 ± 9.6 0.130
DBP (mmHg) 76.1 ± 8.8 72.2 ± 7.2 0.018
MAP (mmHg) 92.4 ± 8.3 88.9 ± 7.3 0.030
Central SBP (mmHg) 109.7 ± 9.1 105.0 ± 9.7 0.016
Central DBP (mmHg) 77.1 ± 8.7 72.6 ± 7.3 0.007
Central MAP (mmHg) 87.7 ± 8.8 84.8 ± 7.8 0.089
Resting HR (beats min−1) 68 ± 10.5 52 ± 7.8 < 0.001
V̇O2peak (ml kg−1 min−1) 42.6 ± 7.1 58.0 ± 8.8 < 0.001
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around its mean as indicated by their  r2 values. The β values associated with LCN2 concentration were small 
and ranged between 0.105 and 0.128, suggesting that the effect of LCN2 on these factors was limited in scale.
In the randomised control trial, we compared the difference between time points in all groups in the inter-
vention study. We had previously reported that the diet + exercise group was the only group to have a significant 
increase in V̇O2peak, which validates the exercise intensity  methodology30. No groups differed significantly from 
one another in the context of age, sex, plasma LCN2 content, or cardiovascular factors, although the BMI between 
groups differed significantly post-intervention (P = 0.0008, Table 8). While LCN2 protein concentration did 
not differ substantially between any of the intervention groups (all P > 0.05, Fig. 3) or within each group when 
comparing initial and post-intervention expression (all P > 0.05), the diet and exercise intervention successfully 
reduced BMI (P = 0.04) compared to the control group (Table 8). This change was not reflected in the cardiovas-
cular health indicators of the intervention groups, as both SBP and DBP remained similar between the control 
and integrated diet-exercise groups. We found that LCN2 levels remained stable over the 12-week interventions 
in all groups (Table 8). Furthermore, initial and post-intervention LCN2 levels were significantly correlated with 
each other between all groups (Table 9). Plasma CRP levels pre-intervention and post-intervention were also 
significantly correlated with each other, but did not correlate with plasma LCN2 levels (Table 10).
Figure 1.  There was no difference in plasma lipocalin-2 (LCN2) protein levels between controls (n = 48) and 
endurance athletes (n = 52) (P = 0.073). Data are expressed as mean ± S.E.M. from two-tailed Man-Whitney 
U-test.
Table 2.  Results of sensitivity analysis performed on athlete status of an individual testing cohort 
demographic and cardiovascular health characteristics as well as LCN2 concentration. Athletes were assigned 
as 1 in the dataset, while controls were assigned as 0. The overall model describes the relationship between 
significant predictors of athlete status and the predicted log odds of the individual tested being an athlete. 
The model correctly predicted athlete status in 94.8% of individuals in our dataset. BMI, body mass index; 
SBP, systolic blood pressure; DBP, diastolic blood pressure; LCN2, lipocalin-2; V̇O2peak maximal aerobic 
(cardiorespiratory) fitness.
Dependent variable Cox & snell  R2 Variables β β Std. Error P value Overall model
Athlete status 0.683
Sex − 5.511 2.8 0.049
log(p/1 − p) = 0.361*Age + 0.74*V̇
O2peak – 5.511 (Male) – 0.695*BMI
BMI − 0.695 0.35 0.047
Age 0.361 0.126 0.004
V̇O2peak 0.74 0.242 0.002
LCN2 Concentration N/A N/A 0.692
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Discussion
Emerging evidence proposes that LCN2 is not merely a biomarker of cardiac and renal diseases, but has a role in 
modulating chronic inflammation and other processes that can lead to these  diseases19,31,32. Chronic inflammation 
is usually associated with poor diet, low physical activity and higher BMI, which are risk factors for all CVDs. 
Here we showed that LCN2 is not modulated by exercise in two independent cohorts. Moreover, a three-month 
intervention with the DASH diet, which is associated with lower inflammation, was not able to lower levels of 
LCN2. Finally, LCN2 levels were highly correlated three months apart, independently of the type of intervention 
and BMI changes. Together, our findings suggest that LCN2 is stable over time and is not modulated by exercise 
nor diet in healthy or overweight/obese people.
When comparisons were drawn between the control and athlete groups, we found no significant difference 
in LCN2 levels, even though conventional cardiovascular health markers were markedly different between the 
groups. Athletes had a significantly healthier cardiovascular profile, consistent with previous studies which have 
found athletes to have longer telomeres and lower general and CVD  mortality33–38. Interestingly, while a recent 
study suggested that LCN2 expression is sex-specific in mice, we could not pinpoint any significant differences 
of plasma LCN2 expression in humans between athletes and controls in male or female  groups39. The ability of 
repeated exercise to rapidly attenuate the initially-seen physiological stress response has been well reported, even 
when the exercise is scaled with the participant’s increasing  fitness40,41. A strong acute phase response may have 
initially occurred in newer athletes which quickly diminished over their time spent training, causing plasma 
LCN2 expression to stabilise. In addition, not all components of the acute phase response may be activated by 
exercise, instead creating a diminished acute phase response. The literature surrounding this topic suggests that 
partial activation of the acute phase response after extreme endurance exercise is  common42. It is possible that 
Table 3.  Characteristics of endurance athletes and controls in males. Data are expressed as mean ± standard 
deviation from two-tailed independent samples t-tests or Mann–Whitney U-tests, with P-values below 
0.05 bolded. Variances were equal between groups for all variables except for resting HR and V̇O2peak. BMI, 
body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, resting heart rate; V̇O2peak, 
maximal aerobic (cardiorespiratory) fitness.
Variable
Controls Endurance athletes
P value(n = 34) (n = 41)
Age (years) 29.7 ± 10.4 33.6 ± 12.0 0.134
BMI (kg/m2) 25.6 ± 2.5 23.0 ± 2.2 < 0.001
SBP (mmHg) 128.0 ± 8.6 125.4 ± 8.3 0.189
DBP (mmHg) 75.9 ± 8.9 73.5 ± 6.7 0.193
MAP (mmHg) 93.0 ± 7.9 90.7 ± 6.6 0.189
Central SBP (mmHg) 110.6 ± 8.1 107.1 ± 9.2 0.107
Central DBP (mmHg) 76.9 ± 8.7 73.9 ± 6.8 0.105
Central MAP (mmHg) 87.6 ± 8.8 86.7 ± 7.0 0.611
Resting HR (beats min−1) 67.2 ± 10.7 52.3 ± 7.3 < 0.001
V̇O2peak (ml kg−1 min−1) 45.8 ± 5.2 59.0 ± 7.2 < 0.001
Table 4.  Characteristics of endurance athletes and controls in females. Data are expressed as mean ± standard 
deviation from two-tailed independent samples t-tests or Mann–Whitney U-tests, with P-values below 
0.05 bolded. Variances were equal between groups for all variables except for age. BMI, body mass index; 




P value(n = 14) (n = 11)
Age (years) 32.4 ± 13.5 32.7 ± 7.4 0.945
BMI (kg/m2) 26.6 ± 3.4 20.9 ± 2.3 < 0.001
SBP (mmHg) 119.9 ± 11.1 112.6 ± 7.1 0.071
DBP (mmHg) 76.6 ± 8.8 67.7 ± 7.4 0.013
MAP (mmHg) 91.0 ± 9.3 82.7 ± 6.3 0.018
Central SBP (mmHg) 107.6 ± 11.3 96.9 ± 7.0 0.015
Central DBP (mmHg) 77.6 ± 8.8 67.8 ± 7.3 0.009
Central MAP (mmHg) 87.7 ± 9.3 77.5 ± 6.9 0.007
Resting HR (beats min−1) 72.0 ± 9.6 52.5 ± 9.9 < 0.001
V̇O2peak (ml kg−1 min−1) 34.7 ± 4.4 54.6 ± 13.1 < 0.001
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circulating LCN2 is unaffected by physiological stress associated with long-term, repeated endurance training, 
and, therefore, would be unchanged in athletes when compared to apparently healthy controls. However, multiple 
studies have found significant changes in post-aerobic exercise serum and plasma LCN2 concentrations, which 
suggests that the acute phase response exhibited in response to moderate to intense aerobic exercise is sufficient 
to cause expression of  LCN243–45. Another possibility is that LCN2 is genetically determined, and is minimally 
influenced by lifestyle factors such as exercise. Indeed, in a previous study we found that the single nucleotide 
polymorphism rs13297295 located near the gene coding LCN2 was a cis-expression quantitative gene locus for 
LCN2 levels in a large cohort, suggesting that plasma LCN2 levels are primarily under genetic  control19.
LCN2 has been proposed as an inflammatory marker for obesity, hyperglycaemia and insulin resistance, and 
has also been found to drive left ventricular pathological cardiac  hypertrophy19,46. Due to LCN2 being under 
genetic control of the NF-kβ and MAPK pathway, both involved in chronic low-grade inflammation found in 
obese and hypertensive individuals, circulating LCN2 expression is possibly stable for as long as inflammation 
status remains relatively unchanged. Our data, however, suggested that plasma LCN2 levels are resistant to modi-
fication by short-term interventions known to decrease inflammation, such as diet or exercise, and levels were 
stable over a period of three months. Indeed, there was no change in LCN2 with a decrease in BMI. Whether lean 
Figure 2.  There was no significant difference in plasma lipocalin-2 (LCN2) protein levels between male 
controls (n = 34) and endurance athletes (n = 41) (P = 0.053), or between female controls (n = 14) and endurance 
athletes (n = 11) (P = 0.847). Data are expressed as mean ± S.E.M. from two-tailed Man-Whitney U-test.
Table 5.  Results of sensitivity analysis performed on male athlete status of an individual testing cohort 
demographic and cardiovascular health characteristics as well as LCN2 concentration. Athletes were assigned 
as 1 in the dataset, while controls were assigned as 0. The overall model describes the relationship between 
significant predictors of athlete status and the predicted log odds of the individual tested being an athlete. 
The model correctly predicted athlete status in 90.5% of individuals in our dataset. BMI, body mass index; 
SBP, systolic blood pressure; DBP, diastolic blood pressure; LCN2, lipocalin-2; V̇O2peak maximal aerobic 
(cardiorespiratory) fitness.
Dependent variable Cox & snell  R2 Variables β β Std. Error P value Overall model
Athlete status 0.676
BMI N/A N/A 0.089
log(p/1 − p) = 0.401(Age) + 0.743(V
O2peak)
Age 0.401 0.148 0.007
VO2peak 0.743 0.254 0.003
LCN2 Concentration N/A N/A 0.956
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Table 6.  Sensitivity analysis performed on blood pressure testing cohort demographic characteristics and 
LCN2 concentration. Significant contributors to the model are bolded, with their specific contributions 
shown in the overall model column. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; LCN2, lipocalin-2.
Dependent variable Adjusted  R2 Variables β β Std. Error P value Overall model
SBP 0.292
Sex 9.938 1.951 < 0.0001
89.605 + 9.938 (Male) + 1.125*BMI
BMI 1.125 0.285 < 0.0001
Age N/A N/A 0.1831
Athlete Status N/A N/A 0.7227
LCN2 Concentration N/A N/A 0.1548
DBP 0.257
Sex N/A N/A 0.322
33.671 + 1.291*BMI + 0.128*LCN
BMI 1.291 0.243 < 0.0001
Age N/A N/A 0.6438
Athlete Status N/A N/A 0.3916
LCN2 Concentration 0.128 0.04 0.0018
Central SBP 0.211
Sex 5.907 2.061 0.0052
74.087 + 0.948*BMI + 5.907 
(Male) + 0.105*LCN—3.382 
(Athlete)
BMI 0.948 0.362 0.0105
Age N/A N/A 0.1996
Athlete Status − 3.382 2.163 0.1217
LCN2 Concentration 0.105 0.05 0.0385
Central DBP 0.229
Sex N/A N/A 0.309
35.927 + 1.27*BMI + 0.114*LCN
BMI 1.27 0.262  < 0.0001
Age N/A N/A 0.91
Athlete Status N/A N/A 0.155
LCN2 Concentration 0.114 0.041 0.007
Table 7.  Sensitivity analysis performed on VO2peak testing cohort demographic characteristics and LCN2 
concentration. Significant contributors to the model are bolded, with their specific contributions shown in the 
overall model column. V̇O2peak maximal aerobic (cardiorespiratory) fitness.
Dependent variable Adjusted  R2 Variables β β Std. Error P value Overall model
VO2peak 0.687
Sex 7.817 1.471  < 0.0001
59.174 + 7.817 (Male) + 13.907 (Ath-
lete) – 0.501*BMI – 0.3*Age
BMI − 0.501 0.271 0.068
Age − 0.3 0.061  < 0.0001
Athlete Status 13.907 1.61  < 0.0001
LCN2 Concentration N/A N/A 0.346
Table 8.  Demographic and cardiovascular characteristics of intervention groups. Data are expressed as 
mean ± standard deviation from one-way ANOVAs comparing values between the three groups, with P values 
below 0.05 bolded. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, 
resting heart rate. *Tukey’s honest significance test comparing BMIs from the control group to the diet and 
exercise intervention, resulting from a mixed ANOVA, with P = 0.04.
Control (n = 17) Diet intervention (n = 20) Diet + exercise interventions (n = 20) P values
Pre-intervention Post-intervention Pre-intervention Post-intervention Pre-intervention Post-intervention Pre-intervention Post-intervention
Age (years) 53.90 ± 5.65 55.46 ± 6.25 54.28 ± 4.43 0.6629
Men/Women (n) 11/6 12/8 12/8 0.9487
BMI (kg/m2) 33.10 ± 3.69 33.38 ± 3.83 32.27 ± 3.81 29.77 ± 3.59 31.82 ± 3.73 28.65 ± 3.52* 0.5862 0.0008
SBP (mmHg) 154.52 ± 25.73 153.38 ± 22.40 157.75 ± 25.64 153.01 ± 26.11 155.07 ± 24.17 144.98 ± 19.97 0.9157 0.4585
DBP (mmHg) 82.54 ± 10.44 78.68 ± 10.57 86.96 ± 11.57 81.69 ± 13.83 87.06 ± 10.06 77.91 ± 10.59 0.3812 0.5944
HR (beats  min−1) 61.98 ± 9.34 61.26 ± 6.98 64.05 ± 8.07 59.11 ± 6.81 58.97 ± 6.96 57.21 ± 8.45 0.1486 0.2839
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Figure 3.  Plasma lipocalin-2 (LCN2) protein levels before and after a randomised control trial. There was 
no difference in LCN2 levels between control (n = 17), dietary intervention (n = 20), or dietary intervention 
and exercise arms (n = 20) (P = 0.37). Comparisons of initial and post-intervention LCN2 concentrations also 
showed no significant changes (P = 0.47, P = 0.60, P = 0.51 for comparisons in the control, diet intervention, and 
dual intervention group respectively). Data are expressed as mean ± S.E.M.
Table 9.  Pearson’s correlations between measured plasma LCN2 concentrations pre- and post-interventions 
per group. Data are from two-tailed Pearson’s correlations, with q-values under 0.05 bolded. FDR, False 
Discovery Rate.
Intervention group r FDR-adjusted q-value
Control 0.708 0.001
Diet intervention 0.703 0.001
Diet and exercise intervention 0.777  < 0.001
All groups combined 0.743  < 0.001
Table 10.  Pearson’s correlations between measured plasma CRP (mg/l) concentrations pre- and post-
interventions per group, as well as correlations with LCN2. Data are from two-tailed Pearson’s correlations, 
with q-values under 0.05 bolded. FDR, False Discovery Rate; LCN2, Lipocalin-2; CRP, C-reactive protein.
Correlations Intervention Group r FDR-adjusted q-value
Pre- and post-intervention plasma CRP correlations
Control 0.557 0.032
Diet intervention 0.629 0.008
Diet and exercise intervention 0.786 0.0003
All groups combined 0.675 < 0.0001
Post-intervention CRP and LCN2 correlations
Control 0.411 0.1616
Diet intervention − 0.220 0.468
Diet and exercise intervention 0.111 0.7429
All groups combined 0.008 0.952
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tissue mass is associated with LCN2 remains to be determined. Although our sensitivity analyses also showed 
that LCN2 was associated with SBP and DBP, the ability of LCN2 to predict blood pressure values was low and 
other traditional risk factors, such as sex and BMI, were more important. Furthermore, the immutable nature of 
plasma LCN2 in response to the exercise or diet regimens and its lack of correlation to various cardiovascular 
health markers lends credence to the applicability of LCN2 as a potential biomarker for CVD, as it may be directly 
influenced by the development of CVD as opposed to being influenced by non-disease related cardiovascular 
health markers (e.g. diet and V̇O2peak). This is further supported by previous research, where LCN2 has been 
found to be a predictor of cardiovascular mortality over an 11 year longitudinal  study47.
Interestingly, we found that decreases in BMI nor changes in plasma CRP over the three month period were 
not associated with changes in LCN2 plasma concentration. The association of circulating LCN2 with BMI 
and other cardiovascular health markers has not been elucidated clearly in the literature, with multiple studies 
conflicting on whether LCN2 and BMI change in  tandem48–51. LCN2 levels, however, are correlated with obesity 
and hyperglycaemia, both of which have been shown to induce and promote a chronic low-grade inflammatory 
 state52–54. Our results support the hypothesis that BMI and LCN2 are not intrinsically linked together, and that 
independent modulation of either variable is possible. Plasma LCN2 levels, however, may be attenuated over 
longer time periods as participants recover from obesity and concomitant chronic low-grade inflammation.
One limitation of this study is the singular type of exercise chosen as the intervention. Many aspects of exer-
cise were controlled in our study, such as duration, frequency, intensity, and mode. However, other regimens 
such as high intensity interval training (HIIT) or resistance training have also shown to be effective exercises for 
cardiovascular health, with HIIT shown to improve both blood pressure and cardiovascular  fitness55. Moreover, 
overweight/obese subjects may display chronotropic incompetence and as such exercise intensity based on 
percentage of maximal heart rate is not always ideal. However, we still observed a significant increase in V̇O2peak 
in the diet + exercise group  only30. Furthermore, as LCN2 levels are positively correlated with left ventricular 
hypertrophy, longitudinal measurements of LCN2 and cardiac size in long-term athletes may yield interesting 
results as exercise induces physiological hypertrophy of the  heart19,56. Additionally, while our study measured 
plasma LCN2, LCN2 content in skeletal muscle or cardiac tissue was not measured. Due to LCN2 being linked to 
the MAPK pathway and because the pathway is heavily involved in muscle regeneration, it is possible that skeletal 
muscle LCN2 content is influenced by acute and long-term  exercise57–59. Our study had several strengths includ-
ing the use of two independent cohorts, one which was a cross-sectional cohort and a randomised control trial. 
Furthermore, it is possible that our intervention timeframe of 12 weeks was insufficient to significantly change 
the inflammatory phenotype that had been built over a long period in overweight or obese individuals. While we 
would expect to still see a change in plasma LCN2 expression within the intervention groups due to the positive 
correlations between BMI and LCN2 expression, along with correlations between BMI and inflammatory markers 
described in the current literature, the change may not have been large enough to elucidate  significance46,60–62.
In conclusion, LCN2 levels were not different between athletes and controls, nor were they modified after 
three months of interventions with diet and exercise. While LCN2 was a significant variable included in mod-
els predicting blood pressure in athletes or controls, the low β values for each suggest that LCN2 has minimal 
effects. Importantly, our data shows that circulating LCN2 plasma concentration is not dependent on BMI, and 
is stable over a period of three months. Pre-intervention LCN2 levels were found to be strongly correlated with 
post-intervention expression. Further research may elucidate a molecular pathway between LCN2 expression 
and multiple renal and CVDs.
Methods
All participants gave written informed consent. The studies were approved by the Alfred Hospital and the Fed-
eration University Australia Human Research Ethics Committees, and followed the Declaration of Helsinki.
Athlete and control participants. Endurance athletes and control subjects involved in a cross-sectional 
analyses were described  elsewhere63,64. Briefly, 52 endurance athletes (cyclists, runners and triathletes) and 48 
controls (aged 18–55) were recruited at Federation University Australia from local advertisements, social media 
and word of mouth (Table 1). Athletes engaged in vigorous endurance exercise at least three times per week, 
for a minimum of one year. Endurance athletes were cyclists, triathletes, middle- or long-distance runners, and 
ultra-marathon runners at state through to international level. The apparently healthy controls were recreation-
ally active but were not engaged in any structured aerobic or resistance exercise training. All subjects were non-
smoking, free from any age-related chronic diseases and not taking any medications. The controls were recrea-
tionally active but were not engaged in any structured aerobic or resistance exercise training. All BP assessments 
were conducted in the AM following an overnight fast. Brachial and central BP was measured with participants 
in a seated position after a 10-min rest period using the SphygmoCor Device (AtCor Medical, Australia). Blood 
pressures were calculated from the average of three measurements, recorded one minute  apart63.
Diet and exercise intervention participants. Overweight and obese middle-aged (45–65 year old) men 
and post-menopausal women who fulfilled Adult Treatment Panel III criteria for metabolic syndrome (MetS) 
were recruited at the Alfred Hospital through newspaper advertisements (clinicaltrials.gov registration number 
NCT00163943, first registration 14/09/2005), as previously  reported30. All subjects were sedentary and not tak-
ing any medication while being free from non-communicable diseases, but were overweight or obese (waist cir-
cumference: ≥ 102 cm for men and ≥ 88 cm for women). None of the participants had type 2 diabetes or a history 
of secondary hypertension, cardiovascular, cerebrovascular, renal, liver, thyroid disease, or drug use known to 
affect these parameters. Supine blood pressure was measured in the clinic as the average of five readings after a 
5-min rest (Dinamap, Model 1846SX; Critikon, Tampa, FL). Body weight was measured in light indoor clothes 
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without shoes, using a digital scale. Waist circumference was measured at the midpoint between the lowest rib 
and iliac crest and hip circumference at the level of the greater trochanters. Stratified randomization by sex and 
hypertension status in blocks of six was used to allocate subjects to one of three groups. Participants were ran-
domly allocated into three arms of a 12-week intervention: control arm (no intervention), diet arm, or exercise 
and diet arm. The diet and exercise intervention protocol has also been reported, which consisted of 40 min of 
bicycle riding on alternating days over 12  weeks30. Exercise was moderate, with participants reaching 65% of a 
predetermined maximum heart rate throughout. Maximum work capacity and maximum oxygen consump-
tion were measured during a "sprint" exercise test. The exercise test was supervised by a cardiologist and was 
performed on a bicycle ergometer, commencing at zero work rate. Each minute the work rate was increased 
20 W until any further increase was prevented by fatigue. The 14-day menu plans, recipes, and prepared meals 
followed a modified Dietary Approaches to Stop Hypertension (DASH) diet, and was composed of 30% fat (6% 
polyunsaturated, 15% monounsaturated, and 9% saturated), 22% protein, and 48% carbohydrate as previously 
 described65,66. They were provided with a 14-day menu plan and recipes, and prepared meals in their homes. 
High sensitivity CRP was measured in fasting samples by immunoturbidimetric assay.
Basal energy requirements were calculated for each individual by indirect calorimetry and energy intake 
was reduced by 600 cal per day as previously described. Subjects were provided with 14-day menu plans and 
recipes and prepared meals in their homes. Participants attended at two weekly intervals for dietary counsel-
ling. Compliance was assessed by prospective 4-day diet records, which were analysed using Australian Food 
Composition Tables (FoodWorks Professional Version 3.02; Xyris Software, Highgate Hill, Australia https ://
xyris .com.au/produ cts/foodw orks-10-profe ssion al/). Sodium, potassium, and protein intake were quantified 
by 24-h urine collections.
Exercise training comprised 40 min bicycle riding on alternate days at a moderate intensity of 65% of prede-
termined maximum heart  rate67. This corresponded to target heart rates within the range 120 –145 bpm during 
exercise. Workload was increased as necessary to maintain target heart rate. Once a week, exercise was performed 
under supervision in our clinical laboratory at the Alfred Hospital Heart Centre. Other sessions were performed 
at the subjects’ homes using provided exercise bicycles and heart rate monitors. Subjects kept records of aver-
age heart rate during each exercise session. Compliance was assessed by review of heart rate records and at the 
end of the intervention from measures of maximal oxygen consumption during a continuous incremental cycle 
ergometry protocol, during which workload was increased by 20 W/min.
Participants in the control group were instructed to maintain their usual dietary and exercise habits. They 
attended our laboratory at the Heart Centre every 3 weeks for body weight and blood pressure assessment.
Plasma measurement of LCN2. All participants gave a fasted (12 h) blood sample collected from the 
antecubital vein using standard phlebotomy procedures. A resting blood sample was collected with participants 
seated. Subjects were asked to refrain from alcohol, caffeine and exercise training at least 24 h before blood 
donation. Plasma was isolated from peripheral blood that was collected into EDTA tubes and stored at − 20 °C. 
Plasma LCN2 abundance was measured in duplicates by enzyme-linked immunosorbent assay (ELISA) run 
in duplicate using the Human NGAL ELISA Kit (ElabScience, E-EL-H0096) according to the supplier’s guide-
lines. Intra-assay coefficients of variability were calculated and only samples with less than 15% variability were 
accepted. Overall inter-assay coefficient of variability was 5.4–9.7%.
Statistical analyses. Outliers were removed using the robust regression and outlier removal algorithm in 
GraphPad Prism (version 8.1.2, GraphPad Software, CA, USA https ://www.graph pad.com/scien tific -softw are/
prism /), using a Q value of 2%. The ROUT algorithm is based on a nonlinear regression to fit an outlier-inde-
pendent curve, which is then used to identify and remove outliers. Two controls and one athlete were excluded 
from the athlete and control cohorts based on the ROUT algorithm, with LCN2 concentrations of 1.638 ng/
mL, 147.714 ng/mL, and 1.514 ng/mL. No participants were found to be outliers for the intervention cohorts. 
Data was first tested for normality using the D’Agostino-Pearson test for normality, and comparisons between 
controls and athletes were performed using two-tailed independent samples t-tests or Mann–Whitney U-tests 
for continuous variables, and chi-squared tests for categorical variables (i.e. biological sex) in SPSS (version 24, 
IBM, NY, USA https ://www.ibm.com/au-en/analy tics/spss-stati stics -softw are), and the equalities of variances of 
variables between groups was computed using Levene’s test. Correlation between LCN2 levels and cardiovascu-
lar heath indicators (including systolic and diastolic blood pressure, mean arterial pressure, and central blood 
pressures) were calculated using Pearson’s correlation, with P-values further corrected for multiple comparisons 
using the ‘p.adjust’ function with the false discovery rate (FDR) correction argument in R (version 3.6.1, R Foun-
dation, Vienna, Austria https ://www.r-proje ct.org/). Sensitivity analysis of LCN2 levels and other significant 
cardiovascular factors was performed through usage of a forward stepwise linear regression analysis in SPSS, 
using the probability of F as an entry and exit factor at 0.15 and 0.20 respectively. An additional sensitivity 
analysis in the form of a forward stepwise binary logistic regression model was performed for the entire cohort 
as well as sex-specific subgroups, testing the predictability of athlete status from LCN2 concentration, cohort 
characteristics, and cardiovascular health indicators. The  R2 (adjusted  R2 values for linear regression models, 
Cox-Snell  R2 values for binary logistic regression models), β, and P-values were reported alongside the general 
model equations.
Comparisons between controls, diet, or diet and exercise arms were performed using a mixed analysis of vari-
ance (MANOVA), with the comparison between the baseline and post-intervention observations as the within-
group effect and the intervention type as the between-group effects. Multiple comparisons were subsequently 
performed using Tukey’s honest significance test. Correlations between initial and post-intervention plasma 
LCN2 concentration were performed using a Pearson’s correlation, with r and FDR-adjusted q-values reported. 
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Data are reported as means, with error bars representing standard error of the mean (S.E.M.) or standard devia-
tion (SD). The mean and standard deviation (S.D.) are reported for cohort characteristics. P or FDR q-values 
below 0.05 were considered significant.
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